![Page 1: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/1.jpg)
SalvadorMartinAlgarraMedicalOncology
ClínicaUniversidaddeNavarraPamplona,Spain
![Page 2: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/2.jpg)
Disclosures• ParticipationinadvisoryboardsandsponsoredlecturesofBMS,MSD,Roche.
![Page 3: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/3.jpg)
Until2010,immunotherapyhadadisappointinghistoryinmetastaticmelanoma
•HDIL-2andadoptiveTcelltherapywerethetreatmentsabletoinducedurableresponses,but…• just inasmallsubsetofpatients,• atthecostofsignificanttoxicity,and•wereonlyavailableinselectedcenters.
Alexander M. Menzies, Georgina V. Long
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
European Journal of Cancer, Volume 49, Issue 15, 2013, 3229–3241
![Page 4: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/4.jpg)
Until2010,immunotherapyhadadisappointinghistoryinmetastaticmelanoma
• Trialswithotherimmune-activeagents,includingbio-chemotherapy,werenegative.
• Severalvaccinesfailedtodemonstrateclinicalbenefit.
Alexander M. Menzies, Georgina V. Long
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
European Journal of Cancer, Volume 49, Issue 15, 2013, 3229–3241
![Page 5: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/5.jpg)
• Inonly5years,advancedmelanomahavebeentransformedfromanincurablediseaseintoacurableone,and…
• Weareonlyatthebeginningofdiscoveringitstransversalimpactthroughoutsolidtumoroncology
After2010,theresultsofimmunotherapytrialsonmetastaticmelanomachangedmarkedly
Semin Oncol 42:429-435,2015
![Page 6: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/6.jpg)
• Theimpactofthefirstscheckpointinhibitors:anti–CTLA-4(cytotoxicT-lymphocyteantigen-4)andanti–PD-1/anti– PD-L1(programmeddeath-1receptoranditsligandPD-L1)isunprecedented.
• Breakingtolerancerepresentsamajorparadigmshift…wehaveenteredanewera.
Semin Oncol 42:429-435,2015
![Page 7: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/7.jpg)
ESMO PRECEPTORSHIP PROGRAMMEIMMUNO-ONCOLOGY
From the essentials of tumour immunology to clinical application
![Page 8: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/8.jpg)
T cell activation and inhibition relies upon co-stimulatory (+) or inhibitory signals (−) to prevent widespread autoimmunity
Alexander M. Menzies, Georgina V. Long. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyondModified from
European Journal of Cancer, Volume 49, Issue 15, 2013, 3229–3241
pembrolizumab
T cell regulation
CTLA-4 is involved in the early phase of T cell activation.
PD-1 is expressed on T cells in the periphery, and interacts with PD-L1 expressed on tissues.
![Page 9: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/9.jpg)
EMACheckpointInhibitorsDrugsApprovalinAdvancedMelanomaDateofissueofmarketingauthorisation fortheEuropeanUnion
• Ipilimumab 13/07/2011• Nivolumab 19/06/2015• Pembrolizumab 17/07/2015• Nivolumab with Ipilimumab 1April2016(“… relativetonivolumabmonotherapy,anincreaseinprogression-freesurvival(PFS)forthecombinationofnivolumab withipilimumab isestablishedonlyinpatientswithlowtumour PD-L1expression…”)
![Page 10: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/10.jpg)
•Anti-CTLA-4therapyinMelanoma
![Page 11: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/11.jpg)
Tremelimumab Phase I• IgG2mAb targetingCTLA-4;Dose: 0.03- 15mg/kg• 39patients (34melanoma)• 29melanomapatients evaluable
• 2CR25+y34+mo• 2PR25+y26+mo• 4SD
• 5SD/PRpatients had DFS23+,24+,26+,35+,36+mo after localthx• 15mg/kgtolerablewith diarrea, dermatitisDLT
Ribasetal.JClinOncol2005;23:8968
![Page 12: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/12.jpg)
CamachoLHetalJCO2009Mar 1;27(7):1075-81
Tremelimumab Phase I/II
![Page 13: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/13.jpg)
Ribasetal.ASCO2008:9011
Tremelimumab Phase IIIfailedtodemonstrateasurvivaladvantage
![Page 14: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/14.jpg)
BMCMed.2016;14:20.AdvancesinimmunotherapyformelanomaJasonM.Redman,GeoffreyT.Gibney,andMichaelB.Atkins
• … datafromthisopen-labelstudymayhavebeenaffectedbycrossoverofpatientsinthechemotherapyarmtoIpilimumab,possiblyconfoundinganypotentialsurvivaldifference.
• Evaluationoftremelimumab’s activityincombinationwithotheragentsisongoing.
Tremelimumab Phase III
![Page 15: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/15.jpg)
IpilimumabPhaseI/II
15
Cohort RR SD Duration Control rate
A (n=34) 1 PR 4 246 15%
B (n=30) 1 PR 3 211 13%
C (n=24) 1 PR + 1 CR 7 263 / 275 39%
Weber et al. ASCO 2007: 8523
![Page 16: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/16.jpg)
Hamidetal.JClinOncol2008;26:9025
![Page 17: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/17.jpg)
Response patterns with Ipilimumab in melanoma
PD = progressive disease; RECIST = Response Evaluation Criteria In Solid Tumors; WHO = World Health Organisation.Graphs for illustrative purposes showing responses to ipilimumab in advanced melanoma.
Figures adapted from Wolchok J, et al. Clin Cancer Res 2009;15:7412–7420.
Time(days)
Tumorch
angefrom
baseline(%
) 50
0
–25
–50
–75
–100
–125
25
100 Therapystart
-63 -21 21 63 105 147 189 231 273 315 357
Responseafterincreaseintumorvolume
BaselineNewlesionsTotal
ThresholdsforresponseorPD(RECIST)
50
25
0
–25
–50
–75
–100
–125
Therapystart
Tumorch
angefrom
baseline(%
)
Time(days)
Stabledisease(RECIST/WHOcriteria)
-63 -21 21 63 105 147 189 231 273 315 357
Tumorch
angefrom
baseline(%
)
Reductionintumorburdenafternewlesions
50
25
0
–25
–50
–75
–100
–125
Time(days)
Therapystart
-63 -21 21 63 105 147 189 231 273 315 357
Tumorch
angefrom
baseline(%
)
50
25
0
–25
–50
–75
–100
–125
Therapystart
Time(days)–63 –21 21 63 105 147 189 231 273 315 357 399 441 483 525
Responseinbaselinelesions(RECIST/WHOcriteria)
MercurynumberONCES15NP00693-01Weber JS et al, Lancet Oncol 16, 375–384, 2015
![Page 18: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/18.jpg)
SurvivalrateafterIpilimumabsecondlineinmelanoma
O´Day et al. ASCO 2009: 9033
![Page 19: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/19.jpg)
PhaseIIItrialIpilimumabsecondline
19
Unresectable Stage III/IV Melanoma HLA-
A2+
Previous treatment with chemotherapy or inmunotherapy
n: 676
RANDOMIZACION
3:1:1
Primary endpoint: Overall SurvivalSecondary endpoint: toxicity
![Page 20: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/20.jpg)
Ipilimumab, the first therapy for unresectable or metastatic melanoma to improve OS in a phase III trial
Median OS, months 95% CI HR P value
Survival rate (%)1-year 2-year
Ipilimumab + gp100 10.0 8.5–11.5 0.68 <0.001 43.6 21.6Ipilimumab 10.1 8.0–13.8 0.66 0.003 45.6 23.5gp100 6.4 5.5–8.7 25.3 13.7
AEs=adverseevents;irAEs =immune-relatedadverseevents..AdaptedfromHodiFS,etal.NEngl JMed.2010;363:711–723;
Prop
ortio
n of
Pat
ient
s Al
ive
(%)
Years
0
20
40
60
80
100
0 1 2 3 4
ThemostfrequentlyreportedirAEs associatedwithipilimumab monotherapy(≥10%,allgrades)inaphaseIIItrialwere:diarrhea(28%),pruritus(24%),andrash(19%)
PhaseIIItrialIpilimumabsecondline
![Page 21: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/21.jpg)
Hodi FS et al. N Engl J Med 2010;363:711-723
![Page 22: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/22.jpg)
Subgroup Analyses of Overall Survival
Hodi FS et al. N Engl J Med 2010;363:711-723
![Page 23: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/23.jpg)
• MedianOSinpatientsreceivingipilimumabplusgp100andipilimumabalonewere10.0and10.1 months,vs6.4 monthsinthosethatreceivedgp100alone.
• 1and2yearOS ratesfortheipilimumab-alonearm,of45.6 %and23.5 %,respectively,withsimilarratesfortheipilimumabplusgp100.
• 1-yearOSratewashigherthanpreviouslyreportedusinganyotherexperimentalregimenforadvancedmelanoma.
PhaseIIItrialIpilimumabsecondline
![Page 24: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/24.jpg)
FirstlinephaseIIIIpilimumabtrial
Untreated unresectable stage III/IV Melanoma
n: 502
1:1
RANDOMIZACION
INDUCTION MANTEINANCE
Ipilimumab 10mg/Kgx4cevery21days
Ipilimumab 10mg/Kgevery12weeks
Placebox4cevery21days
Placebo every 12 weeks
Week1 Week 24Week 12
Dacarbacine 850mg/m2X8cevery21days
Dacarbacine 850mg/m2X8cevery21days
![Page 25: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/25.jpg)
Similarresultsinfirstandsecondline
• Nolongtermdifferencesinsurvival• ChemotherapytoxicitymaylimitIpilimumabadministration
• ChemotherapymaydepleteCD4lymphocytes
• CombinationwithFotemustine withsimilarresults
![Page 26: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/26.jpg)
• IpilimumabdemonstratedclinicalactivityinearlyphasetrialsandwasapprovedbytheFDAfollowingthereleaseofphaseIIIdata,whichshowedasignificantlyimprovedOS
![Page 27: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/27.jpg)
Kaplan-Meier estimates of overall survival in patients treated with ipilimumabplus dacarbazine (DTIC) or placebo plus DTIC in phase III CA184-024 study.
Michele Maio et al. JCO 2015;33:1191-1196
![Page 28: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/28.jpg)
MS(95%CI):11.4mo (10.7–12.1)
3yOS%(95%CI):22mo(20–24)1,861patientsfrom10prospectiveand2retrospectivestudieswithIpilimumab
SchadendorfD,etal.JClinOncol.2015;33:1889-1894.
SchadendorfD,etal.ClinOncol.2015;33:1889-1894.
![Page 29: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/29.jpg)
IPIat3mg/kg(n=965)
IPIat10mg/kg(n=706)
OtherDosingRegimens(n=190)
MedianOS,mo(95%CI)
11.4(10.3-12.5)
11.1(9.9-13.0)
12.4(10.4-15.1)
3-ysurvivalrates,(95%CI)
21%,(17-24)
24%,(21-28)
20%.(14%-26)
SchadendorfD,etal.JClinOncol.2015;33:1889-1894.
MedianOSshowedaplateauat21%inthesurvivalcurvebeginningaroundyear3
• CTLA4wasthefirstimmunecheckpointreceptortobetargeted• Long-termsurvivaldatafrom10prospectiveand2retrospectivetrials(N=1861patients)
![Page 30: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/30.jpg)
CA184-169: Study Design
IPI 3 mg/kgQ3W × 4(n = 362)
IPI 10 mg/kgQ3W × 4(n = 365)
IPI 3 mg/kgQ3W × 4(n = 32)
IPI 10 mg/kgQ3W × 4(n = 23)
Previously Treated/Untreated Metastatic MELb
(N = 727)Stratification• M0 + M1a + M1b
vs M1c withoutbrain metastases vsM1c with brain metastases
• Prior treatment (y/n)• ECOG PS (0/1) Week 1 Week 24
Ran
dom
ize
1:1
aAfter initial response (or stable disease ≥3 months) and subsequent progressive disease in the absence of intolerable toxicity.bPatients could not be treated with BRAF/PD-1 therapy.ECOG PS = Eastern Cooperative Oncology Group performance status; Q3W = every 3 weeks.
• Enrollment period: March 2012 to August 2012• No crossover allowed between treatment arms
Initial treatment phase Re-treatment phasea
![Page 31: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/31.jpg)
OS: Randomized Patients
31
Aliv
e (%
)
Time (Months)
0
10
20
30
40
50
60
70
80
90
100
0 6 12 21 27 33 39 45 483 9 18 24 30 36 4215
IPI 10 mg/kgIPI 3 mg/kg
OSIPI 10 mg/kg
n = 365IPI 3 mg/kg
n = 362Events (%) 262 (72) 279 (77)Median (95% CI), mo 15.7 (11.6, 17.8) 11.5 (9.9, 13.3)
HR (95% CI) 0.84 (0.70, 0.99)Log-rank P value 0.04
Minimum OS follow-up: ~43 mo
Number of patients at risk
IPI 10 mg/kg 365 253 196 151 126 118 105 16 0306 217 161 137 120 111 94181
IPI 3 mg/kg 362 253 168 118 95 83 76 8 0310 205 131 107 87 80 71146
54%
48% 38%
31% 31%
23%
![Page 32: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/32.jpg)
Summary/Conclusions
• Significant improvement in OS with IPI 10 mg/kg vs IPI 3 mg/kg in patients with untreated melanoma.
• No differences were observed for the secondary endpoints of PFS/RR.• IPI 10 mg/kg was associated with higher rates of treatment-related
AEs and AEs leading to discontinuation• Although the treatment landscape has evolved for first-line, the
clinical utility of IPI in refractory patients warrants further evaluation
32
![Page 33: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/33.jpg)
![Page 34: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/34.jpg)
JournalofNeuro-Oncology2014,Volume118: 109–116EfficacyandsafetyofipilimumabinpatientswithadvancedmelanomaandbrainmetastasesQueiroloPetal.
ipilimumab inpatientswithmelanomaandbrainmetastases
![Page 35: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/35.jpg)
Efficacyandsafetyofipilimumab inpatientswithpre-treated,uvealmelanoma
Ann Oncol. 2013;24(11):2911-2915.
![Page 36: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/36.jpg)
•Adjuvanttherapy
![Page 37: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/37.jpg)
AdjuvantInterferon
DFS5y GS5yearsIFNalfa2b 37% 46%Observation 26% 37%
Kirkwood JM,elal.JClin Oncol 14:7-171996
![Page 38: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/38.jpg)
Alexander M M Eggermont , AMM et al The Lancet Oncology, 2015
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
![Page 39: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/39.jpg)
N Engl J Med 2016;375:1845-1855
Study Overview
The 5-year survival rate with ipulimumab was 11 percentage points higher than that with placebo
(65% vs. 54%), but there were substantial immune-related toxic effects.
![Page 40: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/40.jpg)
Kaplan–Meier Estimates of Recurrence-free Survival (RFS), Overall Survival, and Distant Metastasis–free Survival (DMFS).
Eggermont AMM et al. N Engl J Med 2016;375:1845-1855
![Page 41: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/41.jpg)
Conclusions
• As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence-free survival, overall survival, and distant metastasis–free survival than placebo.
• There are more immune-related adverse events with ipilimumab than with placebo.
Eggermont AMM et al. N Engl J Med 2016;375:1845-1855
Study Overview
![Page 42: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/42.jpg)
•AntiPD-1therapyinMelanoma
![Page 43: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/43.jpg)
PEMBROLIZUMAB
![Page 44: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/44.jpg)
• 44%OR• 10mg/Kg>50%RR• RRnot modified by priorIpilimumab
Hamidetal2013NEJM
2013
![Page 45: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/45.jpg)
Robert C et al. N Engl J Med 2015;372:2521-2532
Progression-free and Overall Survival.
Original Article
Pembrolizumab versus Ipilimumab in Advanced Melanoma
N Engl J Med 372(26):2521-2532, 2015
![Page 46: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/46.jpg)
Prespecified Subgroup Analysis of Progression-free and Overall Survival, According to Pembrolizumab Regimen.
Robert C et al. N Engl J Med 2015;372:2521-2532
N Engl J Med 372(26):2521-2532, 2015
![Page 47: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/47.jpg)
Study Overview
In a multinational, randomized study, pembrolizumab produced significantly improved progression-free and overall
survival and less high-grade toxicity than did ipilimumab in patients with metastatic
melanoma.
N Engl J MedVolume 372(26):2521-2532
June 25, 2015
![Page 48: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/48.jpg)
KEYNOTE-006Trial:pembrolizumab vsIpilimumab
• The6-moPFSrateswere47.3%,46.4%,and26.5%forpembrolizumab Q3W,pembrolizumab Q2W,andIPI
• OSwasimprovedoverIPIafter202deathsoccurred(HR0.60;95%CI(0.43-0.84),P =.0013forQ2W;HR0.56,95%CI(0.40-0.78),P =.0003forQ3W)andORRwas33%vs12%,P =.00002
• 6-moOSrateswere85%,88%,and75%.PFSandOSbenefitsofpembrolizumab wereobservedacrossallsubgroupsassessed
• At12monthsposttreatment,OSrateswere74%and68%forthe2pembrolizumabarms,respectively,and58%forIPI
• Theoutcomewithpembrolizumab wassuperiortoIPIinallsubset analysesofprespecifiedgroups,includingPD-L1-positivevsPD-L1-negativetumors
RibasA,etal.AACR2015.AbstractCT101.
![Page 49: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/49.jpg)
NIVOLUMAB
![Page 50: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/50.jpg)
Nivolumab PhaseIStudy:MelanomaPatients
• Studydesign– Nivolumab IVq2wover8-wkcyclesforupto12cycles– Dosingforpatientswithmelanoma:0.1,0.3,1,3,and10mg/kg
• Eligibility:1-5previoussystemicregimens,noactivebrainmetastases,nochronicautoimmunecondition
Sznol M, et al. ASCO 2013.
![Page 51: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/51.jpg)
Nivolumab PhaseIStudy:ResponseinMelanoma
• ORR:31%(acrossdoses)– 41%at3mg/kg– 4%unconventionalresponses– 45%ofresponsesevidentat8wks
• Medianresponsedurationof2yrs
Sznol M et al. ASCO 2013..
ChangeinTargetT
umor
Lesio
ns(%
)
10.0
0.10.31.03.0
Dose, mg/kg200
150
100
50
0
-50
-100
![Page 52: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/52.jpg)
Topalian 2012NEJM
Nivolumab PhaseIStudy:ResponseinMelanoma
![Page 53: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/53.jpg)
• MedianOSwas22.0months.
• 1- and2-yearsurvivalrateswere62%and43%,respectivelyd
Topalian SL,etal.JClinOncol.2014;32:1020-1030
Nivolumab PhaseIStudy:SurvivalinMelanoma
![Page 54: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/54.jpg)
OSPa
tient
s (%
)
Mos Since Treatment Initiation
100908070605040302010
00 3 6 9 1215182124273033363942454851
Died/TreatedMedian, Mos
(95% CI)
60/107 16.8 (12.5-31.6)
1-yr OS: 62%
2-yr OS: 43%
Sznol M, et al. ASCO 2013
PFS
Patie
nts
(%)
Mos Since Treatment Initiation
1009080706050403020100
0 3 6 9 12 15 18 21 24 27 30 33 36
Events/TreatedMedian, Mos
(95% CI)
77/107 3.7 (1.9-9.1)
1-yr PFS: 36%2-yr PFS: 27%
Median PFS: 3.7 mos
Nivolumab PhaseIStudy:SurvivalinMelanoma
![Page 55: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/55.jpg)
Phase IIItrials ofnivolumab 3mg/kgCA209-037yCA209-066
MARZO2015LANCET ENERO2015NEJM
![Page 56: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/56.jpg)
Nivo postIpi:Phase 3CA209-037
Treatuntilprogression*
orunacceptable
toxicity
R2:1
Nivolumab3mg/kgIVQ2W
Investigator’schoiceofchemotherapy(ICC):
• Dacarbazine 1000mg/m2 Q3W
OR• CarboplatinAUC6IVandpaclitaxel175mg/m2 Q3W
Advancedmelanomawhoprogressedafteripilimumab(N=405)
Stratifiedby:
• PD-L1expression†
• BRAFstatus• BORtoprioripilimumab
OpenLabel
Treatment N†CR+PR,
nORR,
%(95%CI)
BestOverallResponse, %
CR PR SD PD UNK
Nivolumab 120 38 32 (24–41) 3 28 23 35 10
ICC 47 5 11 (4–23) 0 11 34 32 23
Weber JS et al, Lancet Oncol 16, 375–384, 2015
![Page 57: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/57.jpg)
Time to and duration of response
Weber JS et al, Lancet Oncol 16, 375–384, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, ontrolled, open-label, phase 3 trial
NivopostIpi:Phase3CA209-037
![Page 58: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/58.jpg)
Nivolumab 1stline:Phase 3:CA209-066:
Treatuntilprogression*orunacceptabletoxicity
Primaryendpoint:
• OS
Secondaryendpoints:
• PFS
• ORR
• PD-L1correlates
R1:1
Nivolumab3mg/kgIV
Q2W+
PlaceboIVQ3W
N=210(206treated)
PlaceboIVQ2W
+Dacarbazine
1000mg/m2 IVQ3W
N=208(205treated)
Double-
blind
EligiblepatientswithunresectablestageIIIorIVmelanoma(N=418)
• BRAFwild-type
• Treatment-naïve
Stratifiedby:
• PD-L1status(≥5%cell-surfacestainingcutoff)
• M-stage
SMR2014
RobertCetal.NEngl .JMed 2014
![Page 59: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/59.jpg)
CA209-066TimetoandDurabilityofResponse
Nivolumab Dacarbazine
Timetoresponse,median(range),mo
2.1(1.6–7.6)
2.1(1.8–3.6)
Durationofresponse,median(range),mo NR 6.0
(3.0–NR)
Ongoingresponseamongrespondersa 72/84(86%) 15/29(52%)
aAtthetimeofthelastfollow-up;NR=Notreached
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78
Time(Week)
Nivolum
ab(84/21
0)Da
carbazine
(29/20
8)
Patie
nts
(no.ofrespo
nders/no
.ran
domize
d)
OntreatmentOfftreatmentFirstresponseOngoingresponseDeath
SMR2014
![Page 60: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/60.jpg)
Table4.CheckMate 066safetyresults3
Results(cont)
Nivolumab(n=206)
Dacarbazine(n=205)
Anygrade
Grade3–4
Anygrade
Grade3–4
Treatment-relatedAEs,n(%) 153(74.3) 24(11.7) 155(75.6) 36(17.6)AEsleadingtodiscontinuationoftreatment,n(%) 14(6.8) 12(5.8) 24(11.7) 19(9.3)Serioustreatment-relatedAEs,n(%) 19(9.2) 12(5.8) 18(8.8) 12(5.9)
3.RobertC,etal.NEngl JMed2015;372:320-30.
![Page 61: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/61.jpg)
CheckMate 066QoL results:TimetofirstdeclineofEORTCQLQ-C30globalhealthstatus/QoL
aTherateofdeteriorationofEORTCQLQ-C30globalhealthstatus/QoLreached50%at276daysforNIVOand179daysforDTIC.bEORTCQLQ-C30MID:≥10points.CI=confidenceinterval;DTIC=dacarbazine;HR=hazardratio;MID=minimalimportantdifference;NIVO=nivolumab.4.LongGV,etal.PresentedattheAmericanSocietyofClinicalOncology2015AnnualMeeting;May29–June2,2015;Chicago,IL, USA.Poster270.
Number ofPts at Risk
1.00
0.8
0.6
0.4
0.2
0.0
Time to First MID Decline (days)b
0 50 100 150 200 250 300 350 400 450
NIVO 147 115 92 68 48 40 29 20 10135 84 56 41 24 13 4 0 0DTIC
HR = 0.66 (95% CI: 0.47, 0.94); P = 0.021Prob
abili
ty o
f Det
erio
ratio
na
![Page 62: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/62.jpg)
Conclusion
Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who
had metastatic melanoma without a BRAF mutation.
CA209-066 Phase IIItrialofnivolumab 3mg/kg
RobertC,etal.NEngl JMed2015;372:320-30.
Study Overview
![Page 63: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/63.jpg)
Cutaneous melanoma: ESMO ClinicalPracticeGuidelinesfordiagnosis,treatmentandfollow-up.
Dummer Retal.AnnOncol 2015Sep;26Suppl 5
• Inthecontextofnewdevelopmentsandmedicalprogress,therearecontinuouslynewexperimentaltreatmentoptionsforpatientswithadvancedmetastaticmelanoma,includingcombinedtherapieswithanti-CTLA4andanti-PD1antibodies,withintralesionaltherapiesandsmallmolecules.
• Patientsshouldpreferentiallybereferredtocentres ofexcellencethatprovideacomprehensiveclinicaltrialprogramme.
![Page 64: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/64.jpg)
Summary• CTL4andPD-1blockageinmetastaticmelanomapatientsachieves:
• Longtermdiseasecontrolinasubsetofpatientsand• Survivalimprovement.
• TheAntiPD-1approvedagents,Pembrolizumab andNivolumab,aremoreactivethantheAntiCTL4approvedagent,Ipilimumab,inadvancedmelanoma.
• Toxicityseemstobemostfrequentinpatientswhoachieveresponse,butisnota“must”.• Nospecificbiomarkersoflongtermresultshavebeenidentifiedsofar,butstudiesonthismatterareongoing.
• Therearealsoanumberofissuespending:• Optimaldose• Durationoftreatment• SequenceandCombinations• Primaryrefractorinessandresistance• Reinduction• ….
![Page 65: Salvador Martin Algarra ESMO final3 · Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond European Journal of Cancer, Volume 49, Issue 15,](https://reader034.vdocuments.mx/reader034/viewer/2022052019/60339a76e83b5145ff04a48d/html5/thumbnails/65.jpg)
Thankyouforyourattention